piperine

antioxidant defense across tissues (diabetic vs normal controls)

modulates

All tissues from diabetic animals exhibited disturbances in antioxidant defense when compared with normal controls

PMID:11083086 · one of two readings recorded this

diabetic effects on brain GSSG, renal glutathione peroxidase and superoxide dismutase, cardiac glutathione reductase and lipid peroxidation

modulates

Treatment with piperine reversed the diabetic effects on GSSG concentration in brain, on renal glutathione peroxidase and superoxide dismutase activities, and on cardiac glutathione reductase activity and lipid peroxidation

PMID:11083086 · one of two readings recorded this

diabetic effects on hepatic GSH, lipid peroxidation, glutathione peroxidase, catalase; renal superoxide dismutase; cardiac glutathione peroxidase and catalase

no effect

Piperine treatment did not reverse the effects of diabetes on hepatic GSH concentrations, lipid peroxidation, or glutathione peroxidase or catalase activities; on renal superoxide dismutase activity; or on cardiac glutathione peroxidase or catalase activities

PMID:11083086 · one of two readings recorded this

hepatic GSSG concentration

increases

Piperine treatment of normal rats enhanced hepatic GSSG concentration by 100% and decreased renal GSH concentration by 35% and renal glutathione reductase activity by 25% when compared to normal controls

PMID:11083086 · one of two readings recorded this

renal glutathione reductase activity

decreases

Piperine treatment of normal rats enhanced hepatic GSSG concentration by 100% and decreased renal GSH concentration by 35% and renal glutathione reductase activity by 25% when compared to normal controls

PMID:11083086 · one of two readings recorded this

renal GSH concentration

decreases

Piperine treatment of normal rats enhanced hepatic GSSG concentration by 100% and decreased renal GSH concentration by 35% and renal glutathione reductase activity by 25% when compared to normal controls

PMID:11083086 · one of two readings recorded this

tissue (liver, kidney, brain, heart) lipid peroxidation, GSH and GSSG content, and catalase, superoxide dismutase, glutathione peroxidase and glutathione reductase activities in streptozotocin-diabetic and normal rats

decreases, renal GSH concentration decreased by 35% in normal rats (hepatic GSSG up 100%, renal glutathione reductase down 25%)

Not recorded as a finding: this platform holds no node for the endpoint

Piperine treatment of normal rats enhanced hepatic GSSG concentration by 100% and decreased renal GSH concentration by 35% and renal glutathione reductase activity by 25% when compared to normal controls.

PMID:11083086 · one of two readings recorded this

Nevirapine AUC(infinity)

increases, n = 8

values of nevirapine were increased by approximately 120%, 167%, 170% and 146%, respectively, when co-administered with piperine

PMID:17963429 · one of two readings recorded this

Nevirapine AUC(t) (0 h to last measurable concentration)

increases, n = 8

values of nevirapine were increased by approximately 120%, 167%, 170% and 146%, respectively, when co-administered with piperine

PMID:17963429 · one of two readings recorded this

Nevirapine Clast

increases, n = 8

values of nevirapine were increased by approximately 120%, 167%, 170% and 146%, respectively, when co-administered with piperine

PMID:17963429 · one of two readings recorded this

Nevirapine Cmax

increases, n = 8

values of nevirapine were increased by approximately 120%, 167%, 170% and 146%, respectively, when co-administered with piperine

PMID:17963429 · one of two readings recorded this

Penetration-aspiration scale severity score

decreases, p = 0.003

the severity score of the penetration-aspiration scale from 3.25 ± 0.51 to 1.85 ± 0.27 (P = 0.003, 1 mM)

PMID:24326980 · one of two readings recorded this

Prevalence of unsafe swallows

decreases, p = 0.001

-57.19% (P < 0.001) at 1 mM

PMID:24326980 · one of two readings recorded this

Prevalence of unsafe swallows

decreases, p = 0.004

-34.48% (P = 0.004) at 150 μM

PMID:24326980 · one of two readings recorded this

Time to laryngeal vestibule closure

decreases, p = 0.05

from 0.380 ± 0.032 to 0.306 ± 0.028 s with 1 mM piperine (P < 0.05)

PMID:24326980 · one of two readings recorded this

Time to laryngeal vestibule closure

decreases, p = 0.001

from 0.366 ± 0.024 to 0.270 ± 0.022 s with 150 μM piperine (P < 0.001)

PMID:24326980 · one of two readings recorded this

repigmentation level of facial vitiligo lesions at 1, 2 and 3 months, topical piperine plus NB-UVB versus placebo plus NB-UVB

increases

Not recorded as a finding: this platform holds no node for the endpoint

Regarding repigmentation at time intervals of 1, 2, and 3 months after treatment, its level in the case group was significantly higher than the control group (p value < .001).

PMID:29781089 · one of two readings recorded this

repigmentation of facial vitiligo lesions at 1, 2 and 3 months after treatment, topical piperine plus NB-UVB versus placebo plus NB-UVB

increases

Not recorded as a finding: this platform holds no node for the endpoint

Regarding repigmentation at time intervals of 1, 2, and 3 months after treatment, its level in the case group was significantly higher than the control group (p value < .001).

PMID:29781089 · one of two readings recorded this

Repigmentation

increases, p = 0.001, n = 63

Regarding repigmentation at time intervals of 1, 2, and 3 months after treatment, its level in the case group was significantly higher than the control group (p value < .001)

PMID:29781089 · one of two readings recorded this

Repigmentation

increases, p = 0.001, n = 63

Regarding repigmentation at time intervals of 1, 2, and 3 months after treatment, its level in the case group was significantly higher than the control group (p value < .001)

PMID:29781089 · one of two readings recorded this

Repigmentation

increases, p = 0.001, n = 63

Regarding repigmentation at time intervals of 1, 2, and 3 months after treatment, its level in the case group was significantly higher than the control group (p value < .001)

PMID:29781089 · one of two readings recorded this

Erythrocyte sedimentation rate

decreases, p = 0.048

erythrocyte sedimentation rate (P = 0.048)

PMID:31168845 · one of two readings recorded this

LDL cholesterol

decreases, p = 0.017

low-density lipoprotein cholesterol (P < 0.017)

PMID:31168845 · one of two readings recorded this

Cholesterol

decreases, p = 0.016

cholesterol (P < 0.016)

PMID:31168845 · one of two readings recorded this

Hemoglobin

decreases, p = 0.025

Hemoglobin (P = 0.025)

PMID:31168845 · one of two readings recorded this

Albumin

unclear

However, except albumin, changes in other parameters were not statistically different between groups

PMID:31168845 · one of two readings recorded this

Alanine aminotransferase (ALT)

decreases, p = 0.035

alanine aminotransferase (P = 0.035)

PMID:31168845 · one of two readings recorded this

Alkaline phosphatase

decreases, p = 0.004

alkaline phosphatase (P = 0.004)

PMID:31168845 · one of two readings recorded this

Aspartate aminotransferase (AST)

decreases, p = 0.042

aspartate aminotransferase (P = 0.042)

PMID:31168845 · one of two readings recorded this

Hematocrit

decreases, p = 0.027

significantly reduced the hematocrit (P = 0.027)

PMID:31168845 · one of two readings recorded this

Iron

decreases, p = 0.026

Iron (P = 0.026)

PMID:31168845 · one of two readings recorded this

NAFLD severity (sonography)

decreases, p = 0.022

which was statistically different compared with the placebo group (P = 0.022)

PMID:31168845 · one of two readings recorded this

NAFLD severity (sonography)

decreases, p = 0.001

administration of curcuminoids plus piperine significantly improved NAFLD severity (P < 0.001)

PMID:31168845 · one of two readings recorded this

Percentage of patients with improved NAFLD

increases, p = 0.058

the percentage of improved patients was marginally higher in the curcuminoids plus piperine group when compared with the placebo group (P = 0.058)

PMID:31168845 · one of two readings recorded this

Total iron-binding capacity

increases, p = 0.003

increased total iron-binding capacity (P = 0.003)

PMID:31168845 · one of two readings recorded this

Catalase (CAT), glutathione reductase (GR) and hs-CRP

no effect

No changes were observed for CAT, GR, and hs-CRP

PMID:36370961 · one of two readings recorded this

Ferritin

decreases, p = 0.018

ferritin: -193.80 ± 157.29 mg/mL versus 51.99 ± 293.25 mg/mL, p = 0.018

PMID:36370961 · one of two readings recorded this

Glutathione peroxidase (GPx) activity

decreases, p = 0.029

GPx activity reduced in the turmeric group (p = 0.029)

PMID:36370961 · one of two readings recorded this

malondialdehyde (MDA) in nmol/mL; assay not named in the abstract

decreases

Not recorded as a finding: the paper never states the instrument the node requires

Turmeric plus piperine was superior to turmeric alone in decreasing MDA and ferritin levels.

PMID:36370961 · one of two readings recorded this

Malondialdehyde (MDA)

decreases, p = 0.003

MDA: -0.08(-0.14/0.01) nmol/mL versus -0.003(-0.10/0.26) nmol/mL, p = 0.003

PMID:36370961 · one of two readings recorded this

serum ferritin

decreases, -193.80 ± 157.29 mg/mL versus 51.99 ± 293.25 mg/mL, p = 0.018

Not recorded as a finding: no ferritin outcome node

There was a reduction in the MDA and ferritin levels in the turmeric/piperine group and in the comparison between groups at the end of the study [MDA: -0.08(-0.14/0.01) nmol/mL versus -0.003(-0.10/0.26) nmol/mL, p = 0.003; ferritin: -193.80 ± 157.29 mg/mL versus 51.99 ± 293.25 mg/mL, p = 0.018].

PMID:36370961 · one of two readings recorded this

Triglycerides

decreases, p = 0.005, n = 68

After 12 weeks | 157.39 ± 41.29 | 214.23 ± 98.10 | 0.005

PMID:38200253 · one of two readings recorded this

Triglycerides

no effect, p = 0.551, n = 68

TG (mg/dL) | Baseline | 234.24 ± 96.94 | 255.67 ± 175.03 | 0.551

PMID:38200253 · one of two readings recorded this

Triglycerides

decreases, p = 0.001, n = 34

Pb | < 0.001 | < 0.001

PMID:38200253 · one of two readings recorded this

Triglycerides

decreases, p = 0.001, n = 34

Pb | < 0.001 | < 0.001

PMID:38200253 · one of two readings recorded this

Bilirubin

no effect, p = 0.428, n = 68

After 12 weeks | 1.19 ± 0.26 | 1.36 ± 0.83 | 0.428

PMID:38200253 · one of two readings recorded this

Bilirubin

no effect, p = 0.791, n = 68

Bilirubin (mg/dL) | Baseline | 1.11 ± 0.38 | 1.09 ± 0.36 | 0.791

PMID:38200253 · one of two readings recorded this

Bilirubin

unclear, p = 0.001, n = 34

Serum levels of ALP and bilirubin significantly declined within case arm (P value = 0.013 and P value < 0.001, respectively)

PMID:38200253 · one of two readings recorded this

Bilirubin

no effect, p = 0.659, n = 34

Pb | < 0.001 | 0.659 | 0.659

PMID:38200253 · one of two readings recorded this

Albumin

no effect, p = 0.451, n = 68

After 12 weeks | 4.77 ± 0.33 | 4.50 ± 0.50 | 0.451

PMID:38200253 · one of two readings recorded this

Albumin

no effect, p = 0.732, n = 68

Albumin (g/dL) | Baseline | 4.71 ± 0.45 | 4.75 ± 0.41 | 0.732

PMID:38200253 · one of two readings recorded this

Albumin

no effect, p = 0.201, n = 34

Pb | 0.201 | 0.006

PMID:38200253 · one of two readings recorded this

Albumin

decreases, p = 0.006, n = 34

Pb | 0.201 | 0.006

PMID:38200253 · one of two readings recorded this

GGT

decreases, p = 0.042, n = 68

After 12 weeks | 54.72 ± 15.23 | 75.40 ± 26.95 | 0.042

PMID:38200253 · one of two readings recorded this

GGT

no effect, p = 0.53, n = 68

GGT (U/L) | Baseline | 53.37 ± 24.48 | 57.20 ± 25.11 | 0.530

PMID:38200253 · one of two readings recorded this

GGT

unclear, p = 0.004, n = 34

Pb | 0.004 | 0.570

PMID:38200253 · one of two readings recorded this

GGT

no effect, p = 0.57, n = 34

Pb | 0.004 | 0.570

PMID:38200253 · one of two readings recorded this

AST

decreases, p = 0.002, n = 68

After 12 weeks | 35.50 ± 10.30 | 47.43 ± 18.02 | 0.002

PMID:38200253 · one of two readings recorded this

AST

no effect, p = 0.19, n = 68

AST (IU/L) | Baseline | 48.76 ± 17.21 | 54.80 ± 19.66 | 0.19

PMID:38200253 · one of two readings recorded this

AST

decreases, p = 0.001, n = 34

Pb | < 0.001 | < 0.001

PMID:38200253 · one of two readings recorded this

AST

decreases, p = 0.001, n = 34

Pb | < 0.001 | < 0.001

PMID:38200253 · one of two readings recorded this

Age at baseline

no effect, p = 0.815, n = 68

Age | 41.76 ± 9.455 | 42.37 ± 11.282 | 0.815

PMID:38200253 · one of two readings recorded this

Alkaline phosphatase

no effect, p = 0.324, n = 68

After 12 weeks | 204.08 ± 62.853 | 191.03 ± 44.539 | 0.324

PMID:38200253 · one of two readings recorded this

Alkaline phosphatase

no effect, p = 0.249, n = 68

Alkaline phosphatase | Baseline | 222.79 ± 82.329 | 201.40 ± 69.141 | 0.249

PMID:38200253 · one of two readings recorded this

Alkaline phosphatase

decreases, p = 0.013, n = 34

Pb | 0.013 | 0.405

PMID:38200253 · one of two readings recorded this

Alkaline phosphatase

no effect, p = 0.405, n = 34

Pb | 0.013 | 0.405

PMID:38200253 · one of two readings recorded this

ALT

decreases, p = 0.001, n = 68

After 12 weeks | 45.34 ± 9.367 | 67.80 ± 24.512 | < 0.001

PMID:38200253 · one of two readings recorded this

ALT

no effect, p = 0.633, n = 68

ALT(IU/L) | Baseline | 81.13 ± 23.649 | 78.20 ± 26.032 | 0.633

PMID:38200253 · one of two readings recorded this

ALT

decreases, p = 0.001, n = 34

Levels of AST and ALT within the both case and control participants were statistically reduced after the study period (both with P value < 0.001)

PMID:38200253 · one of two readings recorded this

BMI at baseline

no effect, p = 0.147, n = 68

BMI | 32.67 ± 4.52 | 31.14 ± 4.09 | 0.147

PMID:38200253 · one of two readings recorded this

Fasting blood sugar (FBS)

decreases, p = 0.011, n = 68

After 12 weeks | 93.50 ± 14.05 | 102.50 ± 11.89 | 0.011

PMID:38200253 · one of two readings recorded this

Fasting blood sugar (FBS)

no effect, p = 0.702, n = 68

FBS (mg/dL) | Baseline | 105.26 ± 21.45 | 107.20 ± 19.97 | 0.702

PMID:38200253 · one of two readings recorded this

Fasting blood sugar (FBS)

decreases, p = 0.001, n = 34

Pb | < 0.001 | 0.147

PMID:38200253 · one of two readings recorded this

Fasting blood sugar (FBS)

no effect, p = 0.147, n = 34

Pb | < 0.001 | 0.147

PMID:38200253 · one of two readings recorded this

HbA1c

no effect, p = 0.767, n = 68

After 12 weeks | 5.81 ± 0.70 | 5.70 ± 0.56 | 0.767

PMID:38200253 · one of two readings recorded this

HbA1c

no effect, p = 0.599, n = 68

HbA1c | Baseline | 5.99 ± 0.91 | 6.10 ± 0.91 | 0.599

PMID:38200253 · one of two readings recorded this

HbA1c

decreases, p = 0.001, n = 34

Pb | < 0.001 | 0.383

PMID:38200253 · one of two readings recorded this

HbA1c

no effect, p = 0.383, n = 34

Pb | < 0.001 | 0.383

PMID:38200253 · one of two readings recorded this

HDL

no effect, p = 0.109, n = 68

After 12 weeks | 43.03 ± 6.01 | 40.86 ± 4.90 | 0.109

PMID:38200253 · one of two readings recorded this

HDL

unclear, p = 0.044, n = 68

HDL (mg/dL) | Baseline | 39.13 ± 6.55 | 42.13 ± 5.51 | 0.044

PMID:38200253 · one of two readings recorded this

HDL

increases, p = 0.001, n = 34

Pb | < 0.001 | 0.311

PMID:38200253 · one of two readings recorded this

HDL

no effect, p = 0.311, n = 34

Pb | < 0.001 | 0.311

PMID:38200253 · one of two readings recorded this

HOMA insulin resistance index

p = 0.596

Not recorded as a finding: one-sided negation 'not significantly declined'; also abstract claims a reduction, text contradicts

Levels of HOMA were not significantly declined in patients of case group in comparison to control patients (P value = 0.596) after the intervention.

PMID:38200253 · one of two readings recorded this

HOMA

no effect, p = 0.596, n = 68

After 12 weeks | 2.89 ± 0.84 | 3.15 ± 0.49 | 0.596

PMID:38200253 · one of two readings recorded this

HOMA

no effect, p = 0.94, n = 68

HOMA | Baseline | 3.40 ± 0.71 | 3.39 ± 0.72 | 0.940

PMID:38200253 · one of two readings recorded this

HOMA

decreases, n = 34

Pb | 0.000 | 0.258

PMID:38200253 · one of two readings recorded this

HOMA

no effect, p = 0.258, n = 34

Pb | 0.000 | 0.258

PMID:38200253 · one of two readings recorded this

LDL

decreases, p = 0.043, n = 68

After 12 weeks | 105.74 ± 18.95 | 118.37 ± 28.79 | 0.043

PMID:38200253 · one of two readings recorded this

LDL

no effect, p = 0.085, n = 68

LDL (mg/dL) | Baseline | 123.47 ± 25.46 | 134.20 ± 24.75 | 0.085

PMID:38200253 · one of two readings recorded this

LDL

decreases, p = 0.001, n = 34

Pb | < 0.001 | < 0.001

PMID:38200253 · one of two readings recorded this

LDL

decreases, p = 0.001, n = 34

Pb | < 0.001 | < 0.001

PMID:38200253 · one of two readings recorded this

Platelets

no effect

The mean levels of platelets at baseline and after intervention were 180.92 ± 27.79 (*103) and 195.42 ± 40.21 (*103) within the case group, respectively

PMID:38200253 · one of two readings recorded this

serum albumin, assay dye not stated

p = 0.451

Not recorded as a finding: one-sided negation 'not significantly reduced'; dye not stated for node requirement

After the study interval, levels of ALP, bilirubin, and albumin were not significantly reduced in case group in comparison to control group (P value = 0.324, 0.428, 0.451, respectively).

PMID:38200253 · one of two readings recorded this

serum alkaline phosphatase, clinical assay

p = 0.324

Not recorded as a finding: one-sided negation 'not significantly reduced' is not no_effect

After the study interval, levels of ALP, bilirubin, and albumin were not significantly reduced in case group in comparison to control group (P value = 0.324, 0.428, 0.451, respectively).

PMID:38200253 · one of two readings recorded this

serum HDL cholesterol

p = 0.109

Not recorded as a finding: one-sided negation 'not significantly lessened'; baseline HDL differed between arms

In contrast, HDL concentrations were not significantly lessened in case group in comparison to control group following the study timeline (P value = 0.109).

PMID:38200253 · one of two readings recorded this

Total cholesterol

decreases, p = 0.001, n = 68

After 12 weeks | 171.55 ± 30.44 | 205.03 ± 37.21 | < 0.001

PMID:38200253 · one of two readings recorded this

Total cholesterol

unclear, p = 0.03, n = 68

Cholesterol (mg/dL) | Baseline | 203.45 ± 44.46 | 225.57 ± 37.80 | 0.030

PMID:38200253 · one of two readings recorded this

Total cholesterol

decreases, p = 0.001, n = 34

Serum concentrations of cholesterol, LDL, and TG were significantly decreased within case arm and control arm after the intervention (all with P value < 0.001)

PMID:38200253 · one of two readings recorded this

Total cholesterol (TC)

decreases, p = 0.032, n = 1038

total cholesterol (TC) (WMD: -6.58 mg/mL, 95% CI: -12.60, -0.55, p = 0.032)

PMID:41057035 · one of two readings recorded this

HDL-C

increases, p = 0.015, n = 1038

high-density lipoprotein cholesterol (HDL-C) (WMD: 1.51 mg/mL, 95% CI: 0.29, 2.72, p = 0.015)

PMID:41057035 · one of two readings recorded this

LDL-C

no effect, p = 0.387, n = 1038

low-density lipoprotein cholesterol (LDL-C) was not statistically significant (WMD: -2.20 mg/mL, 95% CI: -7.22, 2.80, p = 0.387)

PMID:41057035 · one of two readings recorded this

Triglycerides (TG)

decreases, p = 0.001, n = 1038

triglycerides (TG) (WMD: -18.64 mg/mL, 95% CI: -29.94, -7.34, p < 0.001)

PMID:41057035 · one of two readings recorded this